New drug candidate reverses obesity in mice
Researchers at Karolinska Institutet may have found a new way to treat obesity and related disorders by targeting the cells’ powerhouses, the mitochondria. A study published in Nature Metabolism shows that a specific class of drugs that block mitochondrial function can reverse diet-induced obesity, fatty liver and diabetes in mice.
Mitochondria are essential for human health, as they process the nutrients in the food we eat and harvest the energy needed for various processes in the cell. They are central regulators of metabolism, which is very dynamic and can be rerouted and reprogrammed according to different needs or in response to disease.
Increased fat metabolism
Professor Nils-Göran Larsson’s research group at Karolinska Institutet has recently developed highly specific drug candidates that block mitochondrial function, and thus cellular energy production, to treat cancer. Now the researchers have shown that these drugs also have a beneficial effect on metabolism in mice.
“Four weeks of treatment led to an unexpected increase in fat metabolism, resulting in a drastic weight loss, a reduction in fat accumulation in the liver and restored glucose tolerance,” says postdoctoral researcher Taolin Yuan at the Department of Medical Biochemistry and Biophysics, Karolinska Institutet.
The treatment was given orally to male obese mice who had been fed a high-fat diet. The surprising effect suggests that blocking the cells’ energy production can reverse obesity and diabetes.
Collaboration with a biotech company
“It’s exciting that we have identified a new potential strategy for treating common diseases like obesity and type 2 diabetes,” says Professor Nils-Göran Larsson. “We now aim to further investigate the mechanisms that can explain the drugs’ effect. We have also initiated a collaboration with a biotech company to see if this can be further developed into a treatment for humans. Still, it will be many years before we know if it works,” he concludes.
The study was financed by the Novo Nordisk Foundation, the Swedish Diabetes Foundation, the Swedish Research Council, the Knut and Alice Wallenberg Foundation, ALF funding, the Swedish Cancer Society and the Swedish Brain Foundation. Nils-Göran Larsson is a scientific founder and holds stock in Pretzel Therapeutics Inc. Three of the coauthors are employees of Lead Discovery Center and are listed as co-inventors on a patent application concerning mitochondrial RNA polymerase inhibitors for the treatment of cancer. The remaining authors declare no competing interests.Publication: “Inhibition of mammalian mtDNA transcription acts paradoxically to reverse diet-induced hepatosteatosis and obesity”, Shan Jiang, Taolin Yuan, Florian A. Rosenberger, Arnaud Mourier, Nathalia R. V. Dragano, Laura S. Kremer, Diana Rubalcava-Gracia, Fynn M. Hansen, Melissa Borg, Mara Mennuni, Roberta Filograna, David Alsina, Jelena Misic, Camilla Koolmeister, Polyxeni Papadea, Martin Hrabe de Angelis, Lipeng Ren, Olov Andersson, Anke Unger, Tim Bergbrede, Raffaella Di Lucrezia, Rolf Wibom, Juleen R. Zierath, Anna Krook, Patrick Giavalisco, Matthias Mann & Nils-Göran Larsson, Nature Metabolism, online 30 April 2024, doi: 10.1038/s42255-024-01038-3.
Contacts
For more information, please contact:
Nils-Göran Larsson, professor
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Sweden
Phone: +46 70 209 71 55
Email: nils-goran.larsson@ki.se
More press photos of Nils-Göran Larsson and Taolin Yuan can be downloaded from KI's mediabank (https://mediabank.ki.se/)
Images
Karolinska Institutet (https://ki.se/en) is one of the world’s leading medical universities. Our vision is to advance knowledge about life and strive towards better health for all. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.
Subscribe to releases from Karolinska Institutet - English
Subscribe to all the latest releases from Karolinska Institutet - English by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Karolinska Institutet - English
The 2024 Nobel Prize in Physiology or Medicine jointly to Victor Ambros and Gary Ruvkun7.10.2024 12:15:58 CEST | Press Release
The Nobel Assembly at Karolinska Institutet has today decided to award the 2024 Nobel Prize in Physiology or Medicine jointly to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation.
Announcement of the Nobel Prize in Physiology or Medicine 202426.9.2024 17:00:00 CEST | Pressinbjudan
The Nobel Prize will be announced on Monday 7 October 2024 at 11.30 am (at the earliest).The announcement will be open only for media representatives who have been accredited in advance.
Breaking the trend: Skin cancer incidence in young adults declines9.9.2024 00:05:00 CEST | Pressmeddelande
The risk of skin cancer for adults under the age of 50 is now decreasing for the first time in Sweden, according to a study from Karolinska Institutet published in JAMA Dermatology.
New research explains differences between men's and women's immune systems4.9.2024 17:00:00 CEST | Pressmeddelande
In a recent study published in Nature, Swedish researchers demonstrate the role of sex hormones in regulating the immune system. This newfound knowledge explains differences between men and women and can be used to develop new immunological medications according to researchers.
Rising temperatures in Africa may increase perinatal deaths3.9.2024 11:00:00 CEST | Pressmeddelande
Heatwaves in sub-Saharan Africa are predicted to become more common due to climate change. A new study by researchers at Karolinska Institutet and others, published in Nature Medicine, reveals a worrying correlation between high temperatures in the final week of pregnancy and an increased risk of stillbirth and early neonatal mortality.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom